Literature DB >> 22749033

Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study.

Sofia Pavanello1, Ugo Fedeli, Giuseppe Mastrangelo, Federica Rota, Kim Overvad, Ole Raaschou-Nielsen, Anne Tjønneland, Ulla Vogel.   

Abstract

Cytochrome P4501A2 (CYP1A2) is a key enzyme for lung carcinogen activation and lung inflammation. We studied the interactions of the CYP1A2 functional variants -3860G/A(rs2069514),-2467T/delT(rs3569413),-163C/A(rs762551)] with occupational/environmental carcinogenic exposures in the development of lung cancer in a case-control study nested in the Danish prospective cohort "Diet, Cancer and Health." At enrollment (1993-1997), blood samples for genotype analyses and information on lifestyle were collected 5 (mean value) years before the onset of the disease. The study population included 425 lung cancer cases and 786 subcohort members, who were gender- and age-matched. We found that -163A carriers were at increased risk of lung cancer (P=0.035) in a multivariate COX regression model, which was adjusted for personal habits (i.e., cumulative smoking, passive smoke at home, alcohol intake, and fruit intake) and occupational exposure. Additionally, the interaction between -2467delT and smoking increases lung cancer risk in males, especially light smokers (<21.5 pack-years, P=0.004). The increased lung cancer risk found in -163C carriers, independent of smoking status, and in -2467delT male smokers, suggests that these variants could influence lung cancer development through different mechanisms (i.e. lung carcinogen activation and lung inflammation).
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749033     DOI: 10.1016/j.cancergen.2012.02.004

Source DB:  PubMed          Journal:  Cancer Genet


  10 in total

Review 1.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

2.  CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis.

Authors:  Zheng Ma; Wei Guo; Taiqian Gong; Hui-Jun Niu; Ru-Wen Wang; Yao-Guang Jiang
Journal:  Tumour Biol       Date:  2013-11-29

3.  Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Wen-Xia Sun; Ying-Hua Chen; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Xu-Liang Shen; Xiao-Feng He; Li-Xia Wu; Wu Wei; Lin Zhang
Journal:  Mol Genet Genomics       Date:  2014-12-04       Impact factor: 3.291

4.  CYP1A2 rs2069514 polymorphism and lung cancer susceptibility: a meta-analysis.

Authors:  Wenlong Shao; Jianxing He
Journal:  Ann Transl Med       Date:  2015-05

Review 5.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

6.  Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk.

Authors:  Hua Liu; Yuli Liang; Hua Liao; Lanying Li; Hongyun Wang
Journal:  Tumour Biol       Date:  2014-06-19

7.  Quercetin significantly inhibits the metabolism of caffeine, a substrate of cytochrome P450 1A2 unrelated to CYP1A2*1C  (-2964G>A) and *1F (734C>A) gene polymorphisms.

Authors:  Jian Xiao; Wei-Hua Huang; Jing-Bo Peng; Zhi-Rong Tan; Dong-Sheng Ou-Yang; Dong-Li Hu; Wei Zhang; Yao Chen
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

8.  Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: evidence from meta-analyses.

Authors:  Vladimir Vukovic; Carolina Ianuale; Emanuele Leoncini; Roberta Pastorino; Maria Rosaria Gualano; Rosarita Amore; Stefania Boccia
Journal:  BMC Cancer       Date:  2016-02-10       Impact factor: 4.430

9.  Investigation of the major cytochrome P450 1A2 genetic variant in a healthy Tibetan population in China.

Authors:  Yongchao Ren; Fang Liu; Xugang Shi; Tingting Geng; Dongya Yuan; Li Wang; Longli Kang; Tianbo Jin; Chao Chen
Journal:  Mol Med Rep       Date:  2017-05-29       Impact factor: 2.952

10.  CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity.

Authors:  Ferenc Fekete; Katalin Mangó; Annamária Minus; Katalin Tóth; Katalin Monostory
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.